Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Trader J who wrote (8469)	2/10/1999 10:22:00 AM
From: Jules	Respond to of 56535

Lung Cancer Prevention Drug Works In Mice A new anti-cancer compound tested on lung cancer in mice has proven safe and effective, according to Lorus Therapeutics, Inc. Lorus made the announcement Tuesday on behalf of its 80%-owned subsidiary, NuChem Pharmaceuticals, Inc. (NuChem). This in vivo study, involving a murine (mouse) lung cancer prevention model, was performed by Dr. José Halperin at Harvard Medical School. The goal of the study was to specifically assess the efficacy of the analogues upon oral administration. Lorus reported that, relative to controls, this efficacy study showed significant inhibition of squamous cell carcinoma tumors by the test compounds after daily oral administrations from three days to 5 weeks -- and that no apparent toxic effect due to the treatment regimen was noted in the animals. The results confirm the efficacy results obtained in an earlier study for several of NuChem's novel anti-cancer compounds, NC407, NC381, NC383 and NC384. One common measure of anti-tumor efficacy is the tumor to control (T/C) value. This value is calculated by measuring the size of a tumor (mm3) in treated subjects relative to control subjects given placebo. A lower T/C value indicates better efficacy. At termination (week 5), the T/C ratios were as follows: NC407, 30.7%; NC381, 44.9%; NC383, 44.1%; and NC384, 55.3%. No apparent toxic effects due to the treatment regimen were presented by the animals. "This is very encouraging news for us because these data reinforce the human colon cancer model efficacy data we reported last week," commented Philippe G. Lacaille, President and CEO of Lorus Therapeutics. "The confirmation of high anti-cancer activity in two different cancer models, the clear evidence of oral efficacy and the continued presentation of low toxicity in the animals is very promising. We look forward to reporting our continuing progress in the near future." The Company reported that further studies to determine the subcutaneous and oral efficacy in human xenograft models and other models are in progress at various sites across North America, including Harvard Medical School and the University of Nebraska Medical Center. Additional results of this preclinical development are expected to be announced over the next several months. The Company's preclinical development program is on schedule, and as previously announced, an IND filing for a Phase I clinical trial is expected by the end of the first quarter of the year 2000. Lorus is a pharmaceutical company that focuses on the development of cancer therapies. Lorus' goal is to capitalize on its pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone or in combination, to successfully manage cancer. Through an active acquisition and in-licensing program, Lorus is building a portfolio of promising cancer drugs. Late stage clinical development and marketing will be done in cooperation with strategic pharmaceutical partners. Related link: Lorus Therapeutics Inc. [Contact: Paul W. Truscott Jr.] 10-Feb-1999